ClinicalTrials.gg
WithdrawnNCT06661811Updated Oct 15, 2026

A Study of CAR-T Cells Targeting Autoimmune Diseases

An interventional study of CAR-T in Autoimmune Diseases, sponsored by Beijing Boren Hospital. Withdrawn at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Beijing Boren Hospital · Not applicable, Interventional, and Treatment

How we know

Why this study was withdrawn
No participants.
Updated Oct 15, 2026Now WithdrawnPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 125 studies in Autoimmune Diseases with a site in China — 72 open to participants now, 78 under way, 7 of them phase 3. Autoimmune Diseases · China.

Enrollment
107th of 113
0 · median 30
Started
2024
with 25 others
No phase
21 of 125
14 open now
Registered
72nd of 125
by date
Lead sponsor
5 of 125
Beijing Boren Hospital

Among the 125 studies in Autoimmune Diseases with a site in China, this one is the 107th largest by enrollment of the 113 interventional ones that give a count, is one of 26 that started in 2024, is one of 21 with no phase, and was the 72nd registered.

Autoimmune Diseases

804 studies on the registry are indexed under Autoimmune Diseases; 273 are open to participants now.

Browse Autoimmune Diseases studies →

Open to participants now

72 of the 125 studies in Autoimmune Diseases with a site in China are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 195 Autoimmune Diseases studies recruiting now, 90 (46%) set no upper age limit and 79 (41%) stop at 75 or younger; 55 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies in Autoimmune Diseases with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and efficacy of CAR-T cell therapy in patients with autoimmune disease.

Read the detailed description

Autoimmune disease refers to the disease in which the immune system reacts to the host's own body and causes damage to tissues and organs.

Autoreactive B cells can self-activate and differentiate into plasma cells releasing large amounts of autoantibodies, while they can also present their own antigens to autoimmune T cells, thus activating T cells and promoting the release of inflammatory factors.

CAR-T cells can theoretically completely deplete abnormal antibody-producing B cells, allowing immune rebuilding and restoring the patient's normal immune function, achieving drug-free survival, which fully reflects the application prospects of CAR-T therapy in autoimmune disease.

03

Conditions studied

  • Autoimmune Diseases

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, between 18 and 56 years old;
  2. Diagnosed with Diseases;
  3. Good organ functions;
  4. Voluntary participates this trial and can comprehend and sign ICF.

Exclusion criteria

Exclusion Criteria:

  1. Had or has active ;
  2. Had been subjected to treatment by CD19 targeted therapy or CAR-T therapy or any gene therapy;
  3. Combined with other disease that needs treatment;
  4. Pregnant or lactating women;
  5. Has other factors that deemed not suitable by investigator.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    CAR-T treatment

    Drug: CAR-T

Interventions

  • DrugCAR-T

    CAR-T cells

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicity

    Time frame: 0~28 day after treatment

  2. Frequency of AEs, SAEs

    Time frame: 0 day to 24 months after treatment

07

Study locations

1 site
  • Beijing Gaobo Boren Hospital
    Beijing, 100070, China
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Nov 2024 to primary completion in Apr 2026, 17 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Apr 2028 → Apr 2026 and completion Jun 2028 → Apr 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2024
First posted
Oct 28, 2024
StartActual
Nov 15, 2024
Primary completionActual
Apr 30, 2026was Apr 2028
CompletionActual
Apr 30, 2026was Jun 2028
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Withdrawn No participants.
changed Oct 15, 2026
Primary completion
Apr 20, 2028→Apr 30, 2026 (actual)
Oct 15, 2026
Study completion
Jun 20, 2028→Apr 30, 2026 (actual)
Oct 15, 2026
Enrollment
12 (estimated)→0 (actual)
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Not yet recruiting→Withdrawn
    Why stopped No participants.
    Primary completion Apr 20, 2028→Apr 30, 2026 (now actual)
    Study completion Jun 20, 2028→Apr 30, 2026 (now actual)
    Enrollment 12 (estimated)→0 (actual)
    + 4 other changes: index terms, verification date, oversight details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06661811
Lead sponsor
Beijing Boren Hospital
Responsible party
Sponsor
First posted
Oct 28, 2024
Start date
Nov 15, 2024
Primary completion
Apr 30, 2026
Completion
Apr 30, 2026
Last update
Oct 15, 2026

Study contacts

Yajing Zhang, MD/PhD
principal investigator · Beijing Gaobo Boren Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion